Next Generation Tumor Targets
Targeting novel tumor antigens for greater specificity and multifunctional anti-tumor activity.
A New Chapter
Synergy Immunotherapeutics (IMT) is committed to serving those in need by creating highly efficacious therapeutics to treat cancer. Synergy IMT focuses primarily on targeting solid tumor survival-regulating antigens discovered at Synergy IMT. Targeting these antigens can decrease tumor growth in culture and in animal tumor models. The identified novel properties of these tumor antigens indicate that targeting them can address tumor drug resistance, tumor heterogeneity, metastasis and the pro-tumor microenvironment.
Emerging Therapeutic Solutions
Novel tumor antigens have been effectively targeted with monospecific antibodies, antibody drug conjugates (ADCs) and innovative multispecific recombinant antibodies and proteins. Given the properties of the tumor antigens, there is high potential for synergy with approved cancer therapeutics to kill tumor cells and induce or revitalize an anti-tumor immune response. AI is integrated to accelerate and enhance development from discovery to investigative new drug.
